Uploaded June 2026 | Updated November 2026, 4 hours ago
As an MBA student, she dreamed up satellite radio as a capstone project and then co-founded Sirius Satellite Radio. When her daughter was diagnosed with a life-threatening condition, she invented a treatment that saved her life — and countless others’ — and started a $3 billion-per-year pharmaceutical company, the first-ever public benefit corporation in pharma.
She is triple Bruin Martine Rothblatt (B.A. ’77, J.D./MBA ’81), chairperson and CEO of biotechnology firm United Therapeutics, and an inventor, Ph.D., medical ethicist and leader in the transhumanism movement. She pioneered the idea of a gender spectrum decades ago, and became the first transgender CEO of a Fortune 500 company.
Rothblatt delivered the 2026 commencement address before UCLA Anderson’s graduating MBA, EMBA, FEMBA and Ph.D. students. She encouraged the graduates to “be open enough to let the ‘strange ideas’ live! Be reasonable later, be curious first.” In an era when “technology can be miraculous or monstrous,” Rothblatt exhorted, “build the future in a way that makes people more human, not less human.”
She remarked the “strange math of personal growth” that enables her in hindsight to say, “If I had known what I didn’t know, I might not have been brave enough to actually try.” Acknowledging the pressure business school graduates might feel to catch up in their careers, she said, “Let me say something, especially to those of you who secretly worry that you’re behind: You’re not behind. In fact, you’re early — early in your leadership, early in your craft, early in the kind of impact that you’ll create that you can’t even imagine yet.”
Learn more about the MBA and Ph.D. commencement ceremony at UCLA Anderson:
https://www.anderson.ucla.edu/news-and-events/signature-events/commencement
#healthtech #UCLAAlumni #careerdevelopment
As an MBA student, she dreamed up satellite radio as a capstone project and then co-founded Sirius Satellite Radio. When her daughter was diagnosed with a life-threatening condition, she invented a treatment that saved her life — and countless others’ — and started a $3 billion-per-year pharmaceutical company, the first-ever public benefit corporation in pharma.
She is triple Bruin Martine Rothblatt (B.A. ’77, J.D./MBA ’81), chairperson and CEO of biotechnology firm United Therapeutics, and an inventor, Ph.D., medical ethicist and leader in the transhumanism movement. She pioneered the idea of a gender spectrum decades ago, and became the first transgender CEO of a Fortune 500 company.
Rothblatt delivered the 2026 commencement address before UCLA Anderson’s graduating MBA, EMBA, FEMBA and Ph.D. students. She encouraged the graduates to “be open enough to let the ‘strange ideas’ live! Be reasonable later, be curious first.” In an era when “technology can be miraculous or monstrous,” Rothblatt exhorted, “build the future in a way that makes people more human, not less human.”
She remarked the “strange math of personal growth” that enables her in hindsight to say, “If I had known what I didn’t know, I might not have been brave enough to actually try.” Acknowledging the pressure business school graduates might feel to catch up in their careers, she said, “Let me say something, especially to those of you who secretly worry that you’re behind: You’re not behind. In fact, you’re early — early in your leadership, early in your craft, early in the kind of impact that you’ll create that you can’t even imagine yet.”
Learn more about the MBA and Ph.D. commencement ceremony at UCLA Anderson:
https://www.anderson.ucla.edu/news-and-events/signature-events/commencement
#healthtech #UCLAAlumni #careerdevelopment










